← Leaderboards
Marlene Rabinovitch
Stanford University
$40,032,014
Attributed
$62,608,350
Total exposure
18
Grants
14
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $9.9M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$82,259,401 · 19
By mechanism
R01$30,433,992 · 6
P01$27,288,258 · 6
R24$10,118,923 · 1
U01$8,726,019 · 1
UG3$1,998,124 · 1
R38$1,755,437 · 1
Top collaborators
- Mark Robert Nicolls15 shared
- Michael P Snyder15 shared
- Joseph C Wu11 shared
- Serpil C. Erzurum5 shared
- Michael Peter Fischbein5 shared
- William E. Grizzle5 shared
- Vallerie Mclaughlin5 shared
- Mark W Geraci4 shared
Most similar at Stanford University
Same institution · by research overlap
- Roham Zamanian$6,654,663
- Edda Frauke Spiekerkoetter$6,465,471
- Jesse M Engreitz$13,286,146
Others in their field
Top investigators on “Blood Vessels”
- Sonia M Thomas · Research Triangle Institute$353,402,726
- Tracy L Nolen · Research Triangle Institute$353,402,726
- Charles Decarli · University Of California At Davis$66,498,201
- Josef Coresh · New York University School Of Medicine$63,693,760
- Sterling C Johnson · St. Joseph'S Hospital And Medical Center$62,000,770
- Robert P Kimberly · University Of Alabama At Birmingham$56,093,149
Research focus
Blood VesselsLungPulmonary Arterial HypertensionCellsPulmonary HypertensionEndothelial CellsResponseFunctional DisorderSmooth Muscle MyocytesMediatingInflammatoryGenesSignal TransductionGene ExpressionInflammationLinkGene Expression RegulationMutationPathologyProteinsPulmonary Artery StructureGrantPreventProduction
Grant awards (105)
1/2 A Phase 2 Study of Elafin (Tiprelestat) for the Treatment of Pulmonary Arterial Hypertension (PAH)$1,998,124
UG3 · FY2025 · HL
Mapping, programming, and correcting gene regulatory sequences for Alagille Syndrome$761,891
R01 · FY2025 · HL
BMPR2, Monocytes and Macrophages in Pulmonary Artery Hypertension$645,730
R01 · FY2025 · HL · contact PI
Project 3: Endothelial and smooth muscle cell programs for pulmonary arterial hypertension$516,060
P01 · FY2025 · HL · contact PI
Stanford Integrated Cardiovascular/Pulmonary Residency Research Training Program$401,041
R38 · FY2025 · HL
Mapping, programming, and correcting gene regulatory sequences for Alagille Syndrome$771,155
R01 · FY2024 · HL
High Shear Stress Alters Gene Regulation in Pulmonary Arterial Hypertension$724,799
R01 · FY2024 · HL · contact PI
BMPR2, Monocytes and Macrophages in Pulmonary Artery Hypertension$680,174
R01 · FY2024 · HL · contact PI
High Shear Stress Alters Gene Regulation in Pulmonary Arterial Hypertension$739,668
R01 · FY2023 · HL · contact PI
R38 Stanford Integrated Cardiovascular/Pulmonary Residency Research Training Program$328,585
R38 · FY2023 · HL
Pulmonary Hypertension in Genetically Modified Mice$753,123
R01 · FY2022 · HL · contact PI
High Shear Stress Alters Gene Regulation in Pulmonary Arterial Hypertension$739,785
R01 · FY2022 · HL · contact PI
The BMP-PPARy Axis and Pulmonary Hypertension$707,790
R01 · FY2022 · HL · contact PI
R38 Stanford Integrated Cardiovascular/Pulmonary Residency Research Training Program$335,366
R38 · FY2022 · HL
Elafin Therapy for Pulmonary Arterial Hypertension$1,729,729
P01 · FY2021 · HL · contact PI
Pulmonary Hypertension in Genetically Modified Mice$749,819
R01 · FY2021 · HL · contact PI
The BMP-PPARy Axis and Pulmonary Hypertension$705,145
R01 · FY2021 · HL · contact PI
The Cellular Response to Elafin in PAH$701,561
P01 · FY2021 · HL · contact PI
High Shear Stress Alters Gene Regulation in Pulmonary Arterial Hypertension$685,156
R01 · FY2021 · HL · contact PI
R38 Stanford Integrated Cardiovascular/Pulmonary Residency Research Training Program$341,990
R38 · FY2021 · HL
Core A: Administrative Core$134,248
P01 · FY2021 · HL · contact PI
Elafin Therapy for Pulmonary Arterial Hypertension$1,729,729
P01 · FY2020 · HL · contact PI
Pulmonary Hypertension in Genetically Modified Mice$746,604
R01 · FY2020 · HL · contact PI
Endothelial Injury, BMPR2 Dysfunction and Macrophage Activation Cause EndMT and PAH$705,629
R01 · FY2020 · HL · contact PI
The BMP-PPARy Axis and Pulmonary Hypertension$702,567
R01 · FY2020 · HL · contact PI
The Cellular Response to Elafin in PAH$701,561
P01 · FY2020 · HL · contact PI
R38 Stanford Integrated Cardiovascular/Pulmonary Residency Research Training Program$348,455
R38 · FY2020 · HL
Core A: Administrative Core$134,248
P01 · FY2020 · HL · contact PI
Elafin Therapy for Pulmonary Arterial Hypertension$1,728,355
P01 · FY2019 · HL · contact PI
Pulmonary Hypertension in Genetically Modified Mice$743,376
R01 · FY2019 · HL · contact PI
Endothelial Injury, BMPR2 Dysfunction and Macrophage Activation Cause EndMT and PAH$721,683
R01 · FY2019 · HL · contact PI
The Cellular Response to Elafin in PAH$701,561
P01 · FY2019 · HL · contact PI
The BMP-PPARy Axis and Pulmonary Hypertension$623,299
R01 · FY2019 · HL · contact PI
Core A: Administrative Core$134,248
P01 · FY2019 · HL · contact PI
Elafin Therapy for Pulmonary Arterial Hypertension$1,870,546
P01 · FY2018 · HL · contact PI
Integrative Omics as a Discovery Tool for Pulmonary Hypertension$757,680
R01 · FY2018 · HL · contact PI
Endothelial Injury, BMPR2 Dysfunction and Macrophage Activation Cause EndMT and PAH$732,720
R01 · FY2018 · HL · contact PI
The Cellular Response to Elafin in PAH$701,561
P01 · FY2018 · HL · contact PI
Pulmonary Hypertension in Genetically Modified Mice$635,911
R01 · FY2018 · HL · contact PI
The BMP-PPARy Axis and Pulmonary Hypertension$589,435
R01 · FY2018 · HL · contact PI
Core A: Administrative Core$134,248
P01 · FY2018 · HL · contact PI
Pulmonary Hypertension Breakthrough Initiative$2,507,257
R24 · FY2017 · HL
Elafin Therapy for Pulmonary Arterial Hypertension$1,790,971
P01 · FY2017 · HL · contact PI
Integrative Omics as a Discovery Tool for Pulmonary Hypertension$1,210,211
R01 · FY2017 · HL · contact PI
Endothelial Injury, BMPR2 Dysfunction and Macrophage Activation Cause EndMT and PAH$776,362
R01 · FY2017 · HL · contact PI
The Cellular Response to Elafin in PAH$701,561
P01 · FY2017 · HL · contact PI
Pulmonary Hypertension in Genetically Modified Mice$628,080
R01 · FY2017 · HL · contact PI
The BMP-PPARy Axis and Pulmonary Hypertension$579,486
R01 · FY2017 · HL · contact PI
Stanford Career Development Program in Omics of Lung Diseases$338,160
K12 · FY2017 · HL · contact PI
Core A: Administrative Core$134,248
P01 · FY2017 · HL · contact PI
Pulmonary Hypertension in Genetically Modified Mice$17,270
R01 · FY2017 · HL · contact PI
Pulmonary Hypertension Breakthrough Initiative$2,518,872
R24 · FY2016 · HL
Integrative Omics as a Discovery Tool for Pulmonary Hypertension$1,246,582
R01 · FY2016 · HL · contact PI
Pulmonary Hypertension in Genetically Modified Mice$620,780
R01 · FY2016 · HL · contact PI
The BMP-PPARy Axis and Pulmonary Hypertension$545,942
R01 · FY2016 · HL · contact PI
Stanford Career Development Program in Omics of Lung Diseases$344,651
K12 · FY2016 · HL · contact PI
Elafin Therapy for Lung Diseases$88,480
P01 · FY2016 · HL · contact PI
Elafin Therapy for Lung Diseases$2,196,011
P01 · FY2015 · HL · contact PI
iPSC Derived EC as Surrogates Using Pulmonary Hypertension as a Prototype Disease$2,160,049
U01 · FY2015 · HL · contact PI
Pulmonary Hypertension Breakthrough Initiative$1,969,871
R24 · FY2015 · HL
Integrative Omics as a Discovery Tool for Pulmonary Hypertension$843,057
R01 · FY2015 · HL · contact PI
Pulmonary Hypertension in Genetically Modified Mice$614,099
R01 · FY2015 · HL · contact PI
Pulmonary Hypertension Breakthrough Initiative$564,952
R24 · FY2015 · HL
The BMP-PPARy Axis and Pulmonary Hypertension$544,448
R01 · FY2015 · HL · contact PI
Elafin to reverse pulmonary arterial hypertension$395,666
P01 · FY2015 · HL · contact PI
Stanford Career Development Program in Omics of Lung Diseases$262,820
K12 · FY2015 · HL · contact PI
Administrative Core$252,074
P01 · FY2015 · HL · contact PI
Elafin Therapy for Lung Diseases$44,940
P01 · FY2015 · HL · contact PI
iPSC Derived EC as Surrogates Using Pulmonary Hypertension as a Prototype Disease$8,140
U01 · FY2015 · HL · contact PI
Pulmonary Hypertension Breakthrough Initiative$2,557,971
R24 · FY2014 · HL
iPSC Derived EC as Surrogates Using Pulmonary Hypertension as a Prototype Disease$2,290,099
U01 · FY2014 · HL · contact PI
Elafin Therapy for Lung Diseases$2,096,783
P01 · FY2014 · HL · contact PI
Pulmonary Hypertension in Genetically Modified Mice$591,707
R01 · FY2014 · HL · contact PI
Elafin to reverse pulmonary arterial hypertension$395,444
P01 · FY2014 · HL · contact PI
Stanford Career Development Program in Omics of Lung Diseases$267,878
K12 · FY2014 · HL · contact PI
Administrative Core$176,396
P01 · FY2014 · HL · contact PI
iPSC Derived EC as Surrogates Using Pulmonary Hypertension as a Prototype Disease$2,223,752
U01 · FY2013 · HL · contact PI
Elafin Therapy for Lung Diseases$2,045,899
P01 · FY2013 · HL · contact PI
Pulmonary Hypertension in Genetically Modified Mice$564,422
R01 · FY2013 · HL · contact PI
Elafin to reverse pulmonary arterial hypertension$384,145
P01 · FY2013 · HL · contact PI
Administrative Core$171,357
P01 · FY2013 · HL · contact PI
Stanford Career Development Program in Omics of Lung Diseases$124,200
K12 · FY2013 · HL · contact PI
Elafin Therapy for Lung Diseases$2,149,054
P01 · FY2012 · HL · contact PI
iPSC Derived EC as Surrogates Using Pulmonary Hypertension as a Prototype Disease$1,297,925
U01 · FY2012 · HL · contact PI
Pulmonary Hypertension in Genetically Modified Mice$582,538
R01 · FY2012 · HL · contact PI
Elafin to reverse pulmonary arterial hypertension$403,512
P01 · FY2012 · HL · contact PI
Administrative Core$179,998
P01 · FY2012 · HL · contact PI
Cell Specific Localization of Altered Gene Expression in Pulmonary Hypertension$79,000
R03 · FY2012 · HL · contact PI
Elafin Therapy for Lung Diseases$2,180,554
P01 · FY2011 · HL · contact PI
iPSC Derived EC as Surrogates Using Pulmonary Hypertension as a Phototype Disease$746,054
U01 · FY2011 · HL · contact PI
Pulmonary Hypertension in Genetically Modified Mice$577,077
R01 · FY2011 · HL · contact PI
The BMP-PPARgamma Axis and Pulmonary Hypertension$564,347
R01 · FY2011 · HL · contact PI
Elafin to reverse pulmonary arterial hypertension$403,512
P01 · FY2011 · HL · contact PI
Identifying the Serine Elastase Elevated in Pulmonary Vascular Disease$201,498
R21 · FY2011 · HL · contact PI
Administrative Core$179,998
P01 · FY2011 · HL · contact PI
Cell Specific Localization of Altered Gene Expression in Pulmonary Hypertension$79,000
R03 · FY2011 · HL · contact PI
The BMP-PPARgamma Axis and Pulmonary Hypertension$569,937
R01 · FY2010 · HL · contact PI
Identifying the Serine Elastase Elevated in Pulmonary Vascular Disease$241,441
R21 · FY2010 · HL · contact PI
The BMP-PPARgamma Axis and Pulmonary Hypertension$565,216
R01 · FY2009 · HL · contact PI
The BMP-PPARgamma Axis and Pulmonary Hypertension$548,035
R01 · FY2008 · HL · contact PI
Pulmonary Hypertension in Genetically Modified Mice$501,835
R01 · FY2008 · HL · contact PI
Pulmonary Hypertension in Genetically Modified Mice$503,575
R01 · FY2007 · HL · contact PI
Pulmonary Hypertension in Genetically Modified Mice$532,143
R01 · FY2006 · HL · contact PI
Pulmonary Hypertension in Genetically Modified Mice$530,124
R01 · FY2005 · HL
Pulmonary Hypertension in Genetically Modified Mice$553,580
R01 · FY2004 · HL